Tonga

Tonga

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.95 (3.23 - 4.59) 2019 Modelled IHME
4.33 (3.58 - 5.06) 2018 Modelled IHME
4.5 (3.66 - 5.35) 2017 Modelled IHME
4.46 (3.55 - 5.26) 2016 Modelled IHME
4.41 (3.39 - 5.26) 2015 Modelled IHME
4.46 (3.44 - 5.26) 2014 Modelled IHME
4.59 (3.57 - 5.36) 2013 Modelled IHME
4.76 (3.72 - 5.53) 2012 Modelled IHME
4.95 (3.89 - 5.72) 2011 Modelled IHME
5.12 (4.03 - 5.93) 2010 Modelled IHME
5.29 (4.17 - 6.11) 2009 Modelled IHME
5.49 (4.33 - 6.37) 2008 Modelled IHME
5.68 (4.47 - 6.68) 2007 Modelled IHME
5.86 (4.59 - 6.92) 2006 Modelled IHME
5.98 (4.61 - 7.12) 2005 Modelled IHME
6.05 (4.63 - 7.17) 2004 Modelled IHME
6.11 (4.66 - 7.20) 2003 Modelled IHME
6.15 (4.67 - 7.25) 2002 Modelled IHME
6.21 (4.68 - 7.33) 2001 Modelled IHME
6.29 (4.67 - 7.45) 2000 Modelled IHME
6.47 (4.71 - 7.62) 1999 Modelled IHME
6.74 (4.82 - 7.95) 1998 Modelled IHME
7.05 (4.96 - 8.36) 1997 Modelled IHME
7.33 (5.16 - 8.76) 1996 Modelled IHME
7.53 (5.30 - 9.04) 1995 Modelled IHME
7.66 (5.46 - 9.12) 1994 Modelled IHME
7.79 (5.60 - 9.24) 1993 Modelled IHME
7.9 (5.76 - 9.36) 1992 Modelled IHME
7.99 (5.90 - 9.43) 1991 Modelled IHME
8.05 (6.03 - 9.51) 1990 Modelled IHME
9.36 (7.28 - 11.67) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.41 (0.24 - 0.55) 2019 Modelled IHME
0.43 (0.24 - 0.58) 2018 Modelled IHME
0.44 (0.24 - 0.61) 2017 Modelled IHME
0.45 (0.23 - 0.63) 2016 Modelled IHME
0.45 (0.22 - 0.65) 2015 Modelled IHME
0.45 (0.22 - 0.64) 2014 Modelled IHME
0.45 (0.22 - 0.62) 2013 Modelled IHME
0.45 (0.23 - 0.62) 2012 Modelled IHME
0.45 (0.23 - 0.62) 2011 Modelled IHME
0.45 (0.23 - 0.61) 2010 Modelled IHME
0.45 (0.24 - 0.61) 2009 Modelled IHME
0.45 (0.24 - 0.62) 2008 Modelled IHME
0.46 (0.24 - 0.62) 2007 Modelled IHME
0.47 (0.24 - 0.63) 2006 Modelled IHME
0.47 (0.25 - 0.65) 2005 Modelled IHME
0.49 (0.26 - 0.67) 2004 Modelled IHME
0.52 (0.28 - 0.71) 2003 Modelled IHME
0.56 (0.30 - 0.76) 2002 Modelled IHME
0.6 (0.32 - 0.83) 2001 Modelled IHME
0.65 (0.34 - 0.89) 2000 Modelled IHME
0.71 (0.37 - 0.98) 1999 Modelled IHME
0.8 (0.40 - 1.09) 1998 Modelled IHME
0.89 (0.44 - 1.21) 1997 Modelled IHME
0.95 (0.47 - 1.31) 1996 Modelled IHME
0.98 (0.48 - 1.37) 1995 Modelled IHME
0.98 (0.48 - 1.36) 1994 Modelled IHME
0.98 (0.48 - 1.35) 1993 Modelled IHME
0.97 (0.48 - 1.34) 1992 Modelled IHME
0.96 (0.48 - 1.30) 1991 Modelled IHME
0.94 (0.48 - 1.26) 1990 Modelled IHME
2.35 (1.63 - 3.42) 2015 Modelled WHO
0.8 2005 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
53 (44 - 62) 2019 Modelled IHME
53 (44 - 62) 2018 Modelled IHME
53 (44 - 63) 2017 Modelled IHME
53 (44 - 63) 2016 Modelled IHME
53 (44 - 63) 2015 Modelled IHME
53 (44 - 63) 2014 Modelled IHME
53 (44 - 63) 2013 Modelled IHME
53 (44 - 63) 2012 Modelled IHME
53 (44 - 63) 2011 Modelled IHME
53 (44 - 63) 2010 Modelled IHME
53 (45 - 63) 2009 Modelled IHME
53 (44 - 63) 2008 Modelled IHME
53 (44 - 63) 2007 Modelled IHME
53 (45 - 63) 2006 Modelled IHME
53 (45 - 63) 2005 Modelled IHME
53 (44 - 63) 2004 Modelled IHME
53 (44 - 63) 2003 Modelled IHME
53 (44 - 63) 2002 Modelled IHME
53 (44 - 63) 2001 Modelled IHME
53 (44 - 63) 2000 Modelled IHME
53 (44 - 64) 1999 Modelled IHME
54 (45 - 64) 1998 Modelled IHME
55 (46 - 65) 1997 Modelled IHME
56 (47 - 66) 1996 Modelled IHME
56 (47 - 66) 1995 Modelled IHME
56 (48 - 66) 1994 Modelled IHME
57 (48 - 66) 1993 Modelled IHME
57 (48 - 66) 1992 Modelled IHME
57 (48 - 67) 1991 Modelled IHME
57 (48 - 67) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
88 2018 Survey/reported WHO/UNICEF
88 2017 Survey/reported WHO/UNICEF
80 2016 Survey/reported WHO/UNICEF
81 2015 Survey/reported WHO/UNICEF
89 2014 Survey/reported WHO/UNICEF
89 2013 Survey/reported WHO/UNICEF
84 2012 Survey/reported WHO/UNICEF
89 2011 Survey/reported WHO/UNICEF
88 2010 Survey/reported WHO/UNICEF
88 2009 Survey/reported WHO/UNICEF
88 2008 Survey/reported WHO/UNICEF
89 2007 Survey/reported WHO/UNICEF
89 2006 Survey/reported WHO/UNICEF
89 2005 Survey/reported WHO/UNICEF
89 2004 Survey/reported WHO/UNICEF
89 2003 Survey/reported WHO/UNICEF
88 2002 Survey/reported WHO/UNICEF
89 2001 Survey/reported WHO/UNICEF
89 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
81 2018 Survey/reported WHO/UNICEF
81 2017 Survey/reported WHO/UNICEF
78 2016 Survey/reported WHO/UNICEF
78 2015 Survey/reported WHO/UNICEF
80 2014 Survey/reported WHO/UNICEF
82 2013 Survey/reported WHO/UNICEF
77 2012 Survey/reported WHO/UNICEF
82 2011 Survey/reported WHO/UNICEF
82 2010 Survey/reported WHO/UNICEF
84 2009 Survey/reported WHO/UNICEF
84 2008 Survey/reported WHO/UNICEF
87 2007 Survey/reported WHO/UNICEF
89 2006 Survey/reported WHO/UNICEF
89 2005 Survey/reported WHO/UNICEF
90 2004 Survey/reported WHO/UNICEF
85 2003 Survey/reported WHO/UNICEF
88 2002 Survey/reported WHO/UNICEF
91 2001 Survey/reported WHO/UNICEF
93 2000 Survey/reported WHO/UNICEF
90 1999 Survey/reported WHO/UNICEF
95 1998 Survey/reported WHO/UNICEF
95 1997 Survey/reported WHO/UNICEF
94 1996 Survey/reported WHO/UNICEF
91 1995 Survey/reported WHO/UNICEF
90 1994 Survey/reported WHO/UNICEF
96 1993 Survey/reported WHO/UNICEF
82 1992 Survey/reported WHO/UNICEF
88 1991 Survey/reported WHO/UNICEF
94 1990 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.69 (0.55 - 0.84) 2019 Modelled IHME
0.68 (0.54 - 0.83) 2018 Modelled IHME
0.68 (0.54 - 0.84) 2017 Modelled IHME
0.68 (0.54 - 0.84) 2016 Modelled IHME
0.68 (0.54 - 0.85) 2015 Modelled IHME
0.69 (0.55 - 0.84) 2014 Modelled IHME
0.69 (0.55 - 0.85) 2013 Modelled IHME
0.7 (0.56 - 0.86) 2012 Modelled IHME
0.7 (0.56 - 0.87) 2011 Modelled IHME
0.71 (0.56 - 0.87) 2010 Modelled IHME
0.71 (0.56 - 0.88) 2009 Modelled IHME
0.71 (0.57 - 0.88) 2008 Modelled IHME
0.72 (0.57 - 0.88) 2007 Modelled IHME
0.72 (0.57 - 0.88) 2006 Modelled IHME
0.72 (0.57 - 0.89) 2005 Modelled IHME
0.72 (0.57 - 0.89) 2004 Modelled IHME
0.72 (0.57 - 0.89) 2003 Modelled IHME
0.72 (0.57 - 0.89) 2002 Modelled IHME
0.72 (0.57 - 0.89) 2001 Modelled IHME
0.72 (0.57 - 0.90) 2000 Modelled IHME
0.73 (0.57 - 0.89) 1999 Modelled IHME
0.73 (0.58 - 0.90) 1998 Modelled IHME
0.73 (0.58 - 0.90) 1997 Modelled IHME
0.74 (0.58 - 0.91) 1996 Modelled IHME
0.74 (0.58 - 0.92) 1995 Modelled IHME
0.74 (0.58 - 0.91) 1994 Modelled IHME
0.74 (0.58 - 0.91) 1993 Modelled IHME
0.73 (0.57 - 0.91) 1992 Modelled IHME
0.73 (0.57 - 0.90) 1991 Modelled IHME
0.72 (0.56 - 0.89) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
20 (14 - 27) 2019 Modelled IHME
20 (14 - 27) 2018 Modelled IHME
20 (14 - 27) 2017 Modelled IHME
20 (14 - 27) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (13 - 27) 2010 Modelled IHME
20 (13 - 27) 2009 Modelled IHME
20 (13 - 26) 2008 Modelled IHME
20 (13 - 26) 2007 Modelled IHME
19 (13 - 26) 2006 Modelled IHME
19 (13 - 26) 2005 Modelled IHME
19 (13 - 26) 2004 Modelled IHME
19 (13 - 26) 2003 Modelled IHME
19 (13 - 26) 2002 Modelled IHME
20 (13 - 27) 2001 Modelled IHME
20 (13 - 27) 2000 Modelled IHME
20 (13 - 27) 1999 Modelled IHME
20 (13 - 26) 1998 Modelled IHME
19 (13 - 26) 1997 Modelled IHME
19 (13 - 26) 1996 Modelled IHME
19 (13 - 26) 1995 Modelled IHME
19 (13 - 26) 1994 Modelled IHME
19 (12 - 26) 1993 Modelled IHME
19 (12 - 26) 1992 Modelled IHME
19 (13 - 26) 1991 Modelled IHME
19 (12 - 26) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
3.95 (%)
2019
(3.23 - 4.59(%))
IHME
HCV (RNA/cAg+)
0.69 (%)
2019
(0.55 - 0.84(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
18
2019
(14 - 24)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
9
2019
(7 - 12)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.41 (%)
2019, latest modelled
(0.24 - 0.55(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
88 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Partners